A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets

Phase 1 Completed 16 enrolled Jiangsu HengRui Medicine Co., Ltd.

RandomizedCrossoverOpen-labelBasic science

Summary

To assess the relative bioavailability of SHR7280 dry suspension and tablets in healthy subjects. To assess the safety and tolerability of a single dose of SHR7280 dry suspension and tablets.

Timeline

Start: 2023-05-23
Primary completion: 2023-06-09
Completion: 2023-10-20

Publications

Liu X, Qin R, Shu C, Shen K, Li X, Ma L, Li X, Li L, Peng J, Huang D, Chen S, Xie Z, Ye L, Duan L. Relative Bioavailability of Single-Dose Oral Administration of Two SHR7280 Formulations (Dry Suspension and Tablets) in Healthy Chinese Volunteers. Clin Drug Investig. 2025 Sep;45(9):643-650. doi: 10.1007/s40261-025-01470-7. Epub 2025 Aug 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR7280	Small molecule	200 mg	Oral

Indications

No indication recorded.